Guoji Yanke Zazhi (Mar 2022)

Safety and efficacy of 0.005% Atropine eye drops on myopia progression in children with low myopia

  • Bing-Xin Zhao,
  • Ao-Fan Zhang,
  • Can Cui,
  • Li Wei,
  • Bin-Bin Li,
  • Xue-Na Pang,
  • Yong Lyu,
  • Wei-Qun Wang,
  • Jun-Jie Zhang,
  • Ai-Cun Fu

DOI
https://doi.org/10.3980/j.issn.1672-5123.2022.3.07
Journal volume & issue
Vol. 22, no. 3
pp. 388 – 393

Abstract

Read online

AIM:To evaluate the safety and efficacy of 0.005% atropine eye drops on myopia control in children with low myopia. METHODS: Prospective one-year controlled study. One hundred and sixteen children with low myopia were divided into two groups(0.005% atropine group and control group)according to the requirements of children and their guardians. The children(n=58)in the 0.005% atropine group wore single-vision(SV)spectacles, with one drop of 0.005% atropine eye drop applied to both eyes once nightly. The children(n=58)in the control group only wore SV spectacles. Repeated measurements of spherical equivalent refractive errors(SERs), axial length(AL), pupil diameter and accommodative amplitude were performed at baseline, and 4, 8 and 12mo after treatment. The discomfort symptoms were also observed.RESULTS: There were no significant increase shown in change in SERs and AL from baseline to 12mo in the 0.005% atropine group and control group(P0.05). Statistically significant differences were all found in pupil diameter increase and accommodative amplitude decrease between two groups( P<0.01). Six eyes(10.3%)were mild photophobic in the early stage in the 0.005% atropine group. Photophobia disappeared in 4 and 2 eyes after using 0.005% eye drops 2 and 4wk, respectively. No children showed any other discomfort symptoms such as blurred vision or allergy in the two groups.CONCLUSION: Compared to wear SV spectacles alone, regular application of 0.005% atropine could somewhat control the progression of myopia in children with low myopia. However, its clinical effect was not obvious.

Keywords